blue cross blue shield glp 1 coverage 2025 usa for some popular GLP-1 medications is set to go away in January Major insurance changes are coming
Description
Between 2025 and 2030, the global pharmaceutical industry faces a Loss of Exclusivity (LOE) wave that puts an estimated $200 billion to $400 billion in branded drug revenue at direct risk.
The results of cardiovascular and kidney outcomes trials involving sodiumglucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease
About 19% of large employers now cover GLP-1 drugs used primarily for weight
Discover what GLP-1 is, its role in the body and how GLP-1-based medications can help manage diabetes and weight
WHY OUR EXPERTLY DESIGNED TEMPLATES ARE A DESIRED MARKETING SOLUTION
Lemme GLP-1 Daily faces lawsuits alleging misleading claims about boosting GLP-1 levels and weight loss
